# Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

> **NCT02399917** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (actual)

## Conditions studied

- Acute Biphenotypic Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **BIOLOGICAL:** Lirilumab

## Key facts

- **NCT ID:** NCT02399917
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-20
- **Primary completion:** 2018-07-12
- **Final completion:** 2018-07-12
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** This study was terminated early due to response rates not meeting the anticipated minimum of 30%.
- **Last updated:** 2019-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02399917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02399917, "Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02399917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*